How Long Does It Take For Ursodeoxycholic Acid To Work?

Ursodeoxycholic acid (UDCA) is a medication that has been used for decades to treat various liver and gallbladder conditions. By promoting bile flow and reducing inflammation, UDCA can help improve symptoms and liver function in conditions like primary biliary cholangitis and primary sclerosing cholangitis. But how long does it take for UDCA treatment to become effective? A review of UDCA, its mechanisms of action, and the standard time frame for biochemical responses and symptom relief are all covered in this piece of writing.

 

Only just over one percent of the general bile acid pool among human beings is composed of the normally found biliary acid, ursodeoxycholic acid. Greater amounts of UDCA used for medicinal purposes, however, could possess an advantageous effect on liver biochemistry and sensations.

 

Primary sclerosing cholangitis (PSC) and primary biliary cholangitis, also known as PBC, are two instances of cholestatic liver disorders that frequently require medical attention. It is believed that UDCA acts by dislodging undesirable bile acids, encouraging bile flow, and lessening inflammation and hepatic bile acid storage. Moreover, UDCA can aid in the breakdown of stones and prevent them from recurring after removal of the gallbladder by enhancing bile flow and liver chemistry.

What is Ursodeoxycholic Acid?

One of the major bile acids that humans manufacture is ursodeoxycholic acid, or UDCA for brevity. It makes up only about 3–5% of total bile acids in a healthy person. Chemically, UDCA is a secondary bile acid formed in the colon by bacteria from another primary bile acid called chenodeoxycholic acid. When used as a medication, UDCA is synthetically manufactured.

 

PBC and PSC are both instances of cholestatic liver conditions for which UDCA is regularly performed. It can help some individuals' symptoms, such as tiredness and itchiness, go down and improve liver enzyme evaluation. Additionally, UDCA is used to disintegrate cholesterol gallstones, particularly in patients unwilling to endure surgery to eliminate their gallbladder.

How Does Ursodeoxycholic Acid Work?

UDCA is thought to improve cholestatic liver disease through a few key mechanisms:

- Displaces toxic bile acids: UDCA can replace more detergent and toxic bile acids like chenodeoxycholic acid in the bile acid pool. This reduces bile acid-induced liver damage.

- Promotes bile flow: By making the bile less viscous and more watery, UDCA enhances bile flow through small ducts inside the liver. This reduces bile acid and bilirubin buildup.

- Anti-inflammatory effects: UDCA seems to inhibit inflammatory pathways and cytokines involved in the inflammation and scarring of liver tissue in cholestatic diseases.

- Protects hepatocytes: UDCA may help prevent bile acid-induced apoptosis (cell death) of liver cells by stabilizing membranes and through other antioxidant effects.

Together, these mechanisms of action help improve liver biochemistry, reduce symptoms, and slow disease progression in patients with chronic cholestatic liver disease. The same properties also allow UDCA to help dissolve cholesterol gallstones.

How Long Does It Take for Ursodeoxycholic Acid to Work?

In most clinical trials and real-world practice, the beneficial effects of UDCA for cholestatic liver disease take around 3-6 months to become evident.

For PBC patients, studies have found that around 40-70% of patients show significant biochemical response to UDCA within 6-12 months of treatment. Biochemical response is indicated by improvements in alkaline phosphatase (ALP) and bilirubin levels. Symptom relief may occur sooner than biochemical changes. One study found that itching improved within 1-2 months in the majority of PBC patients on UDCA.

 

In PSC patients, most studies show improvements in liver enzymes and symptoms after around 6 months of UDCA therapy. One analysis found UDCA therapy helped lower ALP and AST levels significantly within 6 months in PSC patients. Another study found that PSC patients had less itching after taking UDCA for 3 months.

 

For gallstone dissolution, it can take anywhere from 6 months to 2 years of continuous UDCA treatment to fully dissolve stones. Larger or calcium-containing stones may be more resistant and can require long-term therapy for up to 2 years. Monitoring stone dissolution with ultrasound every 6-12 months allows adjustment of UDCA dosage accordingly.

Factors That Affect the Response to Ursodeoxycholic Acid Treatment

Several factors can influence how well an individual responds to UDCA therapy:

- Disease severity: Patients with later-stage cholestatic liver disease often have a poorer response compared to earlier cases. UDCA Powder works better when initiated soon after diagnosis.

- Underlying disorders: Conditions like inherited disorders of bile metabolism, inflammatory bowel disease, and hepatitis B/C infection reduce UDCA efficacy.

- Age: Older patients tend to respond more slowly to UDCA compared to younger individuals.

- Genetic factors: Variations in certain genes involved in bile acid metabolism can affect UDCA response.

- Adherence: Strict adherence to daily UDCA is crucial. Missing frequent doses reduces effectiveness.

- Other medications: Drugs like cholestyramine, phenobarbital, and rifampicin may interfere with UDCA action when taken together.

Making appropriate lifestyle modifications like avoiding alcohol, eating a low-fat diet, and losing weight can also improve outcomes. Overall, close monitoring and follow-up helps optimize individual response.

Potential Side Effects and Risks of Ursodeoxycholic Acid

UDCA is generally well-tolerated, with mild side effects like:

- Diarrhea or nausea

- Abdominal bloating and pain

- Rash or itching

- Headache

- Formation of gallstones during UDCA treatment is rare but can occur in some susceptible individuals. Also, rapid stone dissolution can briefly cause stone colic in some patients.

Rarely, UDCA use can worsen certain underlying liver conditions like primary biliary cirrhosis and autoimmune hepatitis. It should be used cautiously in people with extrahepatic biliary obstruction. High UDCA doses for prolonged periods may increase liver fibrosis over time in some PBC patients based on one study. Periodic monitoring helps detect potential issues or non-response.

Conclusion

In summary, ursodeoxycholic acid provides an effective pharmacological treatment for certain chronic cholestatic liver diseases and gallstone dissolution. The therapeutic benefits take around 3-6 months to become evident biochemically, with symptom relief often occurring sooner. Individual factors like disease severity and age affect the response. Close medical follow-up allows for optimal dosing and monitoring of treatment efficacy and side effects. For suitable candidates, adhering to UDCA therapy as directed provides prolonged liver protection and improved quality of life.

 

Hongda Phytochemistry Co., Ltd. prides itself on offering a range of flexible services to meet the diverse needs of our clients. As a direct producer, we readily accommodate customized production and Packaging requests, ensuring that the final product aligns perfectly with your specific requirements. Additionally, we are pleased to provide free samples, allowing you to experience the quality of our offerings firsthand. Moreover, our newly established capsule production workshop enables us to tailor capsule products according to your unique specifications. We are also actively engaged in global Exhibitions, including but not limited to the European CPHI, European International Vitafoods, European Food Ingredients Exhibition FIE, Functional Food and Healthy Food Exhibition FFFI, and American SSE.

 

At Hongda Phytochemistry, we are dedicated to delivering excellence in every aspect of our operations. We specialize in providing high-quality UDCA Powder, and our professional team is readily available to address any inquiries you may have about this product or other related offerings. For further information, please feel free to consult our team at duke@hongdaherb.com.

References:

1. Lindor KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med. 1997;336(10):691–695.

2. Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991;324(22):1548–1554.

3. Tint GS, Salen G, Colalillo A, et al. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med. 1982;97(3):351–356.

4. Pares A, Caballería L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006;130(3):715–720.

5. Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992;16(3):707–714.